| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4468
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7092
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7061 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4468
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-04 |
| filingDate |
2004-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2006-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2006525315-A |
| titleOfInvention |
A transdermal dosage form with an anti-tamper function comprising an active drug component and an adverse drug component distal to the active drug layer |
| abstract |
The present invention comprises a transdermal dosage form comprising an active drug component having a skin contacting surface, an adverse drug component, and a barrier. The dosage form comprises at least one groove that passes between the proximal and distal surfaces of the active agent component. The barrier is inserted between the active agent component and the adverse agent component. In one aspect, the barrier is permeable to the selected solvent and impermeable to diffusion of active and adverse agents in the absence of the solvent. In another aspect, the barrier is discontinuous and impervious to diffusion of active and adverse agent, and the dosage form includes at least one groove that passes between the skin contacting surface and the adverse agent component. It becomes. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2010222269-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017505312-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013524275-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2006525370-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8778382-B2 |
| priorityDate |
2003-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |